Page 305 - FINAL PROGRAMME 2017

P-701 Non-equivalence of anti-müllerian hormone automated assays - clinical implications for use as a companion diagnostic for individualised gonadotrophin dosing
S. Iliodromiti1, B. Salje1, D. Dewailly2, C. Fairburn3, R. Fanchin4, M. Gaudoin3, H.W.R. Li5, K. Lukaszuk6, E.H.Y. Ng5, P. Pigny7, T. Tadros4, S.M. Nelson1
1School of Medicine- University of Glasgow, Obstetrics and Gynaecology, Glasgow, United Kingdom
2Hopital Jeanne de Flandre- Centre Hospitalier Regional Universitaire, Service de Gynecologie Endocrinienne et Medecine de la Reproduction de Lille, Lille, France
3GCRM Ltd, GCRM Ltd, Glasgow, United Kingdom
4University of Paris-Ouest, Obstetrics and Gynaecology, Paris, France
5The University of Hong Kong- Queen Mary Hospital, Department of Obstetrics and Gynaecology, Hong Kong, Hong Kong
6NVICTA Fertility and Reproductive Center, NVICTA Fertility and Reproductive Center, Gdansk, Poland
7Centre de Biologie Pathologie- Centre Hospitalier Regional Universitaire de Lille, Laboratoire de Biochimie and Hormonologie, Lille, France
P-702 Ovarian volume as a surrogate marker of ovarian recovery following ovarian stimulation with different triggers of oocyte maturation: kisspeptin, GnRH agonist and human chorionic gonadotropin
R. Islam1, A. Abbara2, S. Clarke2, G. Christopoulos1, A. Comninos3, R. Salim1, S. Lavery1,
G. Trew1, W. Dhillo3
1Imperial College NHS Healthcare Trust, Reproductive medicine, London, United Kingdom 2Imperial College London-, Investigative medicine, London, United Kingdom
3Imperial College London, Investigative medicine, London, United Kingdom
P-703 A modi ed natural protocol for frozen-thawed embryo transfer – Don't mind the LH surge (It's the progesterone that matters). A proof of concept study
A. Weiss1,2, S. Baram1,2, R. Beck-Fruchter1, S. Goldman1, Y. Geslevich1
1Emek Medical Center, Obstetrics and Gynecology, Afula, Israel
2Technion - Israel Institute of Technology, Rappaport Faculty of Medicine, Haifa, Israel
P-704 Effect on endometrial histology and pharmacokinetics of different dose regimens of progesterone vaginal pessaries, in comparison with progesterone vaginal gel and placebo
I. Duijkers1, I. Klingmann2, M. Wargenau3, R. Prinz3, S. Hrafnsdottir4, T. Magnusdottir4, R. Levy-Toledano5, C. Klipping1
1Dinox BV, Groningen, The Netherlands
2Pharmaplex bvba, Wezembeek-Oppem, Belgium
3M.A.R.C.O. GmbH & Co, Düsseldorf, Germany
4Actavis Group PTC ehf, Hafnarfjordur, Iceland
5Teva Pharmaceutical Europe BV, Amsterdam, The Netherlands
FINAL PROGRAMME I GENEVA, SWITZERLAND – 2 TO 5 JULY 2017 305
POSTERS